Corticosteroid plus β₂-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis

Gang Wang¹,²,³†, Xin Zhang¹,²†, Hong Ping Zhang¹,², Lei Wang¹,², De Ying Kang⁴, Peter J. Barnes⁵ and Gang Wang¹,²*

Abstract

Background: Current guidelines recommend a single inhaler maintenance and reliever therapy (SMART) regimen for moderate to severe asthma. However, evidence for the inhaled corticosteroid plus fast-onset-acting β₂-agonist (ICS/FABA) as reliever therapy in management of intermittent and mild asthma patients is lacking.

Objective: To systematically explore efficacy and safety of the proof-of-concept of the ICS plus FABA regimen in a single inhaler as reliever therapy across children and adults with intermittent and mild persistent asthma.

Methods: We searched online bibliographic databases for randomized controlled trials (RCTs) involving the as-needed use of ICS/FABA as monotherapy in intermittent or mild asthma patients. The primary outcomes were exacerbations and the hazard ratio (HR) of the time to first exacerbation.

Results: Six RCTs (n = 1300) met the inclusion criteria. Compared with the as-needed FABA regimen, the as-needed use of ICS/FABA as monotherapy statistically reduced exacerbations (RR = 0.56, P = 0.001). Compared with regular ICS regimen, the as-needed ICS/FABA therapy had slightly higher risk of exacerbations (RR = 1.39, P = 0.011). The HR for time to first exacerbations in the ICS/FABA regimen was significantly lower when compared with FABA regimen (HR = 0.52, P = 0.002) but had no difference when compared with ICS regimen (HR = 1.30, P = 0.286). The corticosteroid exposure in the daily ICS regimen was 2- to 5-fold compared with as-needed use of ICS/FABA regimen.

Conclusions: Our analysis shows that the ICS/FABA as a symptom-driven therapy may be a promising alternative regimen for the patients with intermittent or mild asthma, but it needs further real-world RCTs to confirm these findings.

Keywords: Combination of corticosteroid and fast-onset-acting β₂-agonist, Inhaled corticosteroids, Short-acting β₂-agonist, Meta-analysis
**Introduction**

Asthma is characterized by airway inflammation, airway hyper-responsiveness, and variable airflow limitation [1], with an estimated 300 million affected individuals in the world [2, 3]. Currently, clinical research and management initiatives primarily focus on severe asthma [4–6], while more than half of patients have intermittent or mild diseases [7–9], and there is a largely unexplored but important burden of disease in this group [10]. Short-acting β₂-agonists (SABA) can quickly relieve the symptoms [11], but it has no significant anti-inflammatory effects [12]. Intermittent or mild asthma patients are recommended to initiate treatment with maintenance of low-dose inhaled corticosteroids (ICS) if they require a SABA more than twice a week [13, 14] or twice a month [1]. In addition, in a real-life setting, poor adherence of ICS as a controller is associated with significant asthma-related morbidity. Furthermore, some patients with intermittent or mild asthma prefer to take anti-asthma therapy intermittently and occasionally when they experience few symptoms [15, 16]. Therefore, alternative strategies for long-term management of intermittent or mild asthma is to be needed.

It is now well established that a fixed combination of ICS/LABA inhaler for both maintenance and reliever therapy (SMART regimen), which significantly reduces the risk of severe exacerbations and systemic corticosteroid exposure compared with standard fixed-dose regimen in moderate and severe asthma patients, has been recommended for patients with steps 3 to 5 in guidelines [1]. However, it could not be generalized to patients with steps 1 and 2 being equivalent to intermittent or mild persistent asthma (GINA steps 1 and 2) (Table 1), because there is a lack of evidence for the combination corticosteroid/fast-onset-acting β₂-agonist (ICS/FABA) in a single inhaler as reliever therapy in the management of these patients. A proof-of-concept study indicated that in patients with mild asthma, the symptom-driven use of ICS and SABA in a single inhaler resulted in efficacy similar to that seen with regular ICS therapy [17]. Hence, in this proof-of-concept systematic review, we systematically explored the efficacy and safety of the ICS plus FABA regimen in a single inhaler as reliever therapy.

### Table 1 Recommendations of step1/2 treatments in different guidelines

| Guidelines                                      | Step 1                                      | Step 2                                      |
|------------------------------------------------|---------------------------------------------|---------------------------------------------|
| GINA [1]                                        | Preferred controller choice, none; Other controller option, low dose ICS; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS; Other controller option, LTRA, theophylline; Reliever, as-needed SABA. |
| NAEPP [13]                                      | Preferred controller choice, none; Other controller option, low dose ICS; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS; Other controller option, cromolyn, LTRA, nedocromil, theophylline; Reliever, as-needed SABA. |
| British Guideline on the Management of Asthma [53] | Preferred controller choice, none; Other controller option, none; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS; Other controller option, chromones, LTRA, theophylline; Reliever, as-needed SABA. |
| The Chinese guideline for Asthma Management and Prevention [54] | Preferred controller choice, none; Other controller option, low dose ICS; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS; Other controller option, LTRA, ICS/LABA; Reliever, as-needed SABA. |
| Spanish guideline on the management of asthma [55] | Preferred controller choice, none; Other controller option, none; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS, LTRA; Other controller option, chromones, theophylline; Reliever, as-needed SABA. |
| Japanese guidelines for adult asthma [56]       | Preferred controller choice, low dose ICS; Other controller option, LTRA, theophylline; Reliever, as-needed SABA. | Preferred controller choice, ICS/LABA; Other controller option, low to medium dose ICS, ICS and LTRA, ICS and theophylline; Reliever, as-needed SABA. |
| The Saudi Initiative for Asthma [57]            | Preferred controller choice, none; Other controller option, none; Reliever, as-needed SABA. | Preferred controller choice, low dose ICS; Other controller option, LTRA; Reliever, as-needed SABA. |

*GINA the Global Initiative for Asthma, NAEPP the National Asthma Education and Prevention Program, ICS inhaled corticosteroids, LTRA Leukotriene receptor antagonists, SABA short-acting β₂-agonist, ICS/LABA inhaled corticosteroids/long-acting β₂-agonist*
compared with the as-needed use of FABA regimen and the daily use of ICS regimen in children and adults with intermittent and mild persistent asthma based on randomized controlled trials.

**Methods**

This study was in adherence to the Preferred Reporting in Systematic Reviews and Meta-Analyses (PRISMA) guidelines [18].

**Selection criteria**

The eligible studies were randomized controlled trials (RCTs) including patients with intermittent or mild persistent asthma. The eligible interventions included the as-needed use of ICS plus FABA regimen as only one treatment in a single inhaler or separate inhalers in comparison with the regular ICS regimen or the as-needed use of FABA regimen. Any types of fast-onset-acting β₂-agonists such as SABA (salbutamol, terbutaline or others) or FABA (formoterol but not salmeterol) were allowed.

**Data sources and searching**

We searched MEDLINE (Ovid), EMBASE (Ovid), Epub Ahead of Print, In-Process & Other Non-Indexed Citations (Ovid) and Cochrane Central Register of Controlled Trials (CENTRAL, Ovid) up to October 10, 2017, for randomized controlled trials involving the as-needed use of ICS/FABA as monotherapy in intermittent or mild asthma patients. To increase sensitivity for founding the intermittent and mild asthma trials, we included broader asthma severity terms contained total asthma spectrum (The medical subject headings (MeSH) terms used as described in Additional file 1: Table S1). There was no language restriction for the search. We also manually reviewed reference lists of relevant reports and contacted with the manufacturer of budesonide/formoterol inhaler (Symbicort®, AstraZeneca AB) for any unpublished studies and/or additional unpublished data from published studies. To identify ongoing trials, we also searched the WHO International Clinical Trials Registry Platform (ICTRP) and ClinicalTrials.gov.

**Study selection**

To validate this proof-of-concept of the combination as-needed use of the ICS plus FABA regimen in intermittent and mild asthma, we included all studies that involved the use of the ICS and the FABA in a single inhaler or separate inhalers as reliever therapy. Two reviewers (XZ & GW) independently selected articles on the basis of title and/or abstract for full text scrutiny. Disagreements were resolved by consensus or, if required, a third reviewer serving as the arbitrator (GW as the corresponding author).

**Data extraction**

Two reviewers independently extracted information from included studies for the following characteristics such as authors, study design, total duration of study, details of any ‘run in’ period, study centers and location, inclusion criteria, exclusion criteria, diagnostic criteria of asthma, asthma severity, sample size, age, gender, baseline lung function, inhaler device, daily dose of steroid presented as beclomethasone dipropionate (BDP) equivalent, adherence, dropouts or withdrawals and outcomes.

**Quality assessment**

The bias risk of the different studies was assessed with the components recommended by the Cochrane Collaboration for randomized trials [19]. These components include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. For each component, individual team members judged whether the risk of bias in a given study was “low,” “high,” or “unclear.” Any disagreements were referred to the third reviewer.

**Primary and secondary outcomes**

The primary objective of this study was to explore the efficacy of the as-needed use ICS/FABA regimen, and therefore the primary outcome was the exacerbations defined by the criteria of moderate to severe exacerbations of American Thoracic Society (ATS)/European Respiratory Society (ERS) [20]. Furthermore, we also calculated the severe exacerbations and the hazard ratio (HR) of the time to first exacerbation after randomization within these included studies.

The secondary outcomes included nocturnal awakenings times, the percentage of asthma symptom-free days, the number of rescue medication required per day, forced expiratory volume in one second (FEV₁) percentage of predicted value. In addition, in terms of the safety profile, we assessed the number of dropout, serious adverse events, corticosteroid exposure and linear growth during the study period just in the children and adolescent subgroup.

**Statistical analysis**

We treated exacerbations data using patients as the unit of analysis (rather than events) to avoid repeating. Where zero counts existed for an dichotomous outcome in one arm of a trial, we added a value of 0.5 to permit meta-analysis, and where zero counts existed in both arms of a trial, we omitted the trial from the analysis of that outcome according to Cochrane principles [19]. We presented dichotomous data as risk ratio (RR), continuous data as the standardized mean difference (SMD) and time-to-event data as hazard ratio (HR) with 95%
confidence intervals. Specially, a software named Get-Data Graph Digitizer v.2.26 [21] (DR MyCommerce, Inc.) was used to dig out the detailed data from Kaplan–Meier curves of the time to first exacerbation for calculating the HR, which was described in detail in the Methods section in this article’s Additional file 1. For missing data, we contacted investigators or study sponsors in order to obtain where possible. Otherwise, we dealt with missing data according to the Cochrane handbook recommending principals [19, 22]. All analyses were performed using an intention to treat approach. For the primary outcome of exacerbations, we calculated the number needed to treat (NNT) for assessing the different levels of risk. Heterogeneity was assessed with the Q statistic and the $I^2$ statistic. A random-effects model [23] was used to pool data if substantial heterogeneity was observed ($I^2 > 50\%$ or $P < 0.1$ for Q statistic), otherwise we used a fixed-effects model [24]. If there were more than 10 trials, a funnel plot would be created to explore possible publication bias. The quality of a body of evidence for primary outcomes was rated using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system [25] (GRADEpro Guideline Development Tool, McMaster University, 2015).

In addition, because adherence is very important in regular or fixed maintenance therapy, we undertook an additional meta-analysis of auxiliary information was performed to pool real-life adherence of the daily use of ICS treatment in patients with persistent asthma who were present in a real-world setting. The detailed method and results were provided in the Methods and Results section in this article’s Additional file 1.

Data were combined with the Stata 14.0 software (College Station, TX). Statistical significance was assumed for $P < 0.05$.

**Results**

**Studies retrieved and characteristics**

Figure 1 shows details of study identification, inclusion, and exclusion. Our search strategy initially yielded 10,612 citations, and the AstraZeneca (AstraZeneca AB) provided thirteen studies. Finally, six RCTs were included in this meta-analysis [17, 26–30].

Table 2 shows the characteristics of the included studies. Generally, there were five parallel trials and one crossover trial [26]. According to the recommendation of the Cochrane Handbook for Systematic Reviews of Interventions [19], we judged the suitability and acceptability of the cross-over design in our study (Additional file 1: Table S2). One thousand and three hundred subjects were included for analysis (Table 2). There were 674 (6 studies; 46.2% female; median age: 25.9 [range: 19.7–65.0]) subjects included in qualitative synthesis (n = 6).
| Variables                                      | Haahela 2006 [27] | Papi 2007 [17] | Papi 2009 [30] | Martinez 2011 [29] | Lazarinis 2014 [28] | Fitzpatrick 2016 [26] |
|------------------------------------------------|-------------------|----------------|-----------------|---------------------|---------------------|-----------------------|
| Countries                                      | Finland and Sweden| Multinational  | Italy           | USA                 | Sweden and Norway    | USA                   |
| Study design                                   | Multicenter,      | Multicenter,   | Multicenter,    | Multicenter,        | Randomized,          | Multicenter,          |
|                                                | randomized,       | randomized,    | randomized,     | randomized,         | double-blind,        | randomized,           |
|                                                | double-blind,    | double-blind,  | double-blind,   | double-blind,       | parallel trial       | double-blind,         |
|                                                | parallel trial    | parallel trial | parallel trial  | parallel trial      |                     | crossover trial       |
| Duration (weeks)                               | 24                | 24             | 12              | 44                  | 6                   | 16                    |
| Diagnostic criteria of asthma                 | GINA              | The EPR-2 guideline | Frequent wheezing* | The EPR-3 guideline | GINA               | The EPR-3 guideline  |
| Asthma severity                               | Intermittent      | Mild           | Mild            | Mild                | Mild                | Mild                  |
| Intervention                                  | ICS/FABA regimen, budesonide/formoterol, 1 inhalation, 160/45 μg each, as-needed; FABA regimen, formoterol, 1 inhalation, 4.5 μg each, as-needed | ICS/FABA regimen, beclomethasone/salbutamol, 1 inhalation, 250/100 μg each, as-needed; FABA regimen, salbutamol, 1 inhalation, 100 μg each, as-needed; ICS regimen, beclomethasone, 1 inhalation, 250 μg each, twice daily | ICS/FABA regimen, beclomethasone/salbutamol, 1 inhalation, 800/1600 μg each, as-needed; FABA regimen, salbutamol, 1 vial nebulization, 2500 μg each, as-needed; ICS regimen, beclomethasone, 1 vial nebulization, 400 μg each, twice daily | ICS regimen, beclomethasone (HFA), 2 inhalations, 40 μg each, twice daily or as-needed; FABA regimen, salbutamol, 1 inhalation, 500 μg each, as-needed; ICS regimen, beclomethasone (HFA), 1 inhalation, 400 μg each, twice daily | ICS regimen, fluticasone propionate, 2 inhalations, 44 μg each, twice daily or as-needed; FABA regimen, salbutamol, 2 inhalations, 90 μg each, as-needed |
| Adherence of daily ICS                        | NA                | 91.62%         | 99.4%           | 85%                 | 98.25%              | 96%                   |
| Beclomethasone equivalent consumption (μg/day, Mean ± SD) | ICS/FABA 162.8 | 110 ± 150.3 | 179.8 ± 256 | 30 | 203.75 ± 100 | 77.14 |
|                                                | ICS –             | 458.1 ± 103.3  | 795.2 ± 81 | 170 | 491.25 ± 15 | 342.86 |
| Number of patients                            | ICS/FABA 45       | 122            | 110            | 74                  | 23                  | NA                    |
|                                                | FABA 47           | 118            | 56             | 74                  | 22                  | NA                    |
|                                                | ICS –             | 106            | 110            | 72                  | 21                  | NA                    |
|                                                | Total 92          | 346            | 276            | 220                 | 66                  | 300                   |
| Age (years, mean ± SD)                        | ICS/FABA 34.8 ± 19.9 | 36.8 ± 13.1 | 2.26 ± 0.79 | 104 ± 28 | 31 ± 12 | NA |
|                                                | FABA 36.5 ± 12.1  | 40.6 ± 13.8 | 2.29 ± 0.78 | 104 ± 32 | 28 ± 12 | NA |
|                                                | ICS –             | 37.9 ± 13.5    | 2.35 ± 0.81    | 108 ± 35 | 26 ± 10 | NA |
|                                                | Total NA          | NA             | NA             | NA                  | NA                  | 3325 ± 1.1            |
| Variables | Hahtela 2006 [27] | Papi 2007 [17] | Papi 2009 [30] | Martinez 2011 [29] | Lazarinis 2014 [28] | Fitzpatrick 2016 [26] |
|-----------|------------------|----------------|----------------|-------------------|--------------------|---------------------|
| Sex (% female) |                   |                |                |                   |            |                     |
| ICS/FABA   | 66               | 59             | 38.2           | 48                | 39                 | NA                  |
| FABA       | 72               | 58.5           | 39.3           | 45                | 72                 | NA                  |
| ICS        | –                | 57.5           | 41.8           | 42                | 52                 | NA                  |
| Total      | NA               | NA             | NA             | NA                | NA                 | 40.3                |
| Number of dropout |               |                |                |                   |            |                     |
| ICS/FABA   | 1                | 22             | 4              | 13                | 1                  | 18\(^b\)            |
| FABA       | 5                | 18             | 3              | 24                | 0                  | –                   |
| ICS        | –                | 17             | 2              | 9                 | 3                  | 12\(^b\)            |

ICS inhaled corticosteroids, FABA fast-onset-acting \(\beta_2\)-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting \(\beta_2\)-agonist

\(^a\)Frequent wheezing defined as a documented history of at least three episodes of wheezing requiring medical attention in the previous 6 months

\(^b\)Treatment failure criteria were met in a single 16-week treatment arm
317 (5 studies; 54.9% female; median age: 23.6 [range: 2.3–40.6] years) and 609 (5 studies; 46.1% female; median age: 23.4 [range: 2.4–39.9] years) subjects in the as-needed use of ICS/FABA regimen, the as-needed use of FABA regimen and in the daily use of ICS regimen, respectively. The diagnostic criteria for asthma in the included studies were based on the guidelines recommendation except for the study by Papi et al. [30] on frequent wheezing in the previous 6 months. There was one study on intermittent asthma and 5 studies on mild persistent asthma. All subjects in these included studies were requested to have the adherence of 75%. The average FEV1 percentage of predicted value were 95.4 (SD = 13.1), 94.8 (SD = 12.0) and 94.0 (SD = 12.1) for the as-needed use of ICS/FABA, as-needed use of FABA and the daily ICS regimens groups, respectively. The ICS/FABA regimens used included beclomethasone/salbutamol, budesonide/formoterol, beclomethasone and salbutamol, beclomethasone/salbutamol and fluticasone propionate and salbutamol, respectively. The regular ICS regimens used involved beclomethasone, budesonide and fluticasone propionate, respectively. The FABA regimens used were presented as formoterol, terbutaline and salbutamol. The median intervention duration was 24 (ranged from 6 to 44) weeks.

The quality of reporting in the reviewed studies was generally good. The risk of bias is shown in Additional file 1: Table S2. All studies were multicenter trials except Lazarinis et al's study [28]. All the included studies were randomized double-blind trials, except the study of Papi et al. [30] was an unclear risk in random sequence generation, Lazarinis et al's study [28] there was an unclear risk in blinding and Haahetla et al's study [27] there was an unclear risk in allocation concealment and blinding.

**Primary outcomes**

Compared with the as-needed FABA regimen, the as-needed use of ICS/FABA as monotherapy statistically reduced moderate to severe exacerbations (RR = 0.56, 95%-CI = [0.40, 0.78], P = 0.001, I² = 56.6%, Fig. 2a, Table 3). The number needed to treat for an additional beneficial outcome (NNTB) was 10 and the number of avoided events per 1000 was 101 (95%-CI = [51, 138]). Compared with regular ICS regimen, the as-needed ICS/FABA regimen had slightly higher risk of moderate to severe exacerbations (RR = 1.39, 95%-CI = [1.08, 1.79], P = 0.011, I² = 45.4%, Fig. 2b), and the number needed to treat for an additional harmful outcome (NNTH) was 17 and the number of excess events per 1000 was 57 (95%-CI = [12, 116]).

We also explored the difference of severe exacerbations [20] between the as-needed ICS/FABA, the regular ICS and the as-needed FABA regimens (Fig. 3). As a result, the as-needed ICS/FABA regimen significantly reduced severe exacerbations (RR = 0.64, 95%-CI = [0.44, 0.95], P = 0.026, I² = 0.0%) compared to FABA regimen and the NNTH was 16 and the number of avoided events per 1000 was 62 (95%-CI = [9, 96]). In comparison with the regular ICS regimen, the as-needed ICS/FABA regimen had increased risk of severe exacerbations (RR = 1.34, 95%-CI = [1.02, 1.75], P = 0.034, I² = 29.2%) and the NNTH was 18 and the number of excess events per 1000 was 56 (95%-CI = [3, 123]).

Like the study by Yancey and colleagues [31], we grouped the data of the time to first exacerbation, obtained by GetData Graph Digitizer [32], into a five-day interval life table and established a life-table curves to illustrate the difference in the time to first exacerbation for each of the three treatments (Fig. 4a). As a result, the hazard ratio (HR) for time to first exacerbations after randomization in the ICS/FABA regimen was significant lower when compared with FABA regimen (HR = 0.520, 95%-CI = [0.345, 0.785], P = 0.002) but did not reach statistical difference when compared with ICS regimen (HR = 1.295, 95%-CI = [0.805, 2.083], P = 0.286) (Fig. 4b).

The quality of evidence body rated by GRADE for primary outcomes is summarized in Table 4. Compared with the as-needed FABA regimen, the as-needed use of ICS/FABA as monotherapy probably reduces moderate to severe exacerbations and the hazard for the time to first exacerbation (moderate-quality evidence). The as-needed ICS/FABA regimen probably has slightly higher risk of moderate to severe exacerbations and increases the hazard for the time to first exacerbation compared with regular ICS regimen (moderate-quality evidence). In addition, compared with FABA regimen, regular ICS regimen probably reduces the hazard for the time to first exacerbation (moderate-quality evidence).

**Secondary outcomes**

Compared with the FABA regimen, the ICS/FABA regimens showed a decrease in nocturnal awakenings (SMD = –0.29, 95%-CI = [–0.49, –0.09], P = 0.004, I² = 8.7%, Table 5) and a marked improvement in FEV1% predicted (SMD = 0.77, 95%-CI = [0.11, 1.44], P < 0.001, I² = 91.3%) but there was no significant difference in the percentage of asthma symptom-free days between these two regimens. The as-needed ICS/FABA regimen had a trend to reduce number of rescue medication required per day but this did not reach a statistical significance (SMD = –0.14, 95%-CI = [–0.29, 0.01], P = 0.076, I² = 18.0%). In comparison with ICS regimen, the as-needed ICS/FABA regimen had a decreased percentage of asthma symptom-free days (SMD = –0.25, 95%-CI = [–0.37, –0.14], P = 0.001, I² = 56.6%).
−0.13], \( P < 0.001 \), \( I^2 = 0.0\% \)) and more rescue medication required per day (SMD = 0.19, 95%-CI = [0.08, 0.31], \( P = 0.001 \), \( I^2 = 16.2\% \)), but there was no statistical significance in nocturnal awakening times and improvement of FEV\(_1\)% predicted between these two regimens.

### Subgroup analysis

We also performed a subgroup analyses based on adults, and children or adolescents. In the adult subgroup, the as-needed ICS/FABA regimen had a significant decrease in moderate to severe exacerbations compared with the FABA regimen (RR = 0.24, 95%-CI = [0.10, 0.54], \( P = 0.001 \), \( I^2 = 0.0\% \), Table 3) and the NNTB was 8 and the number of avoided events per 1000 was 120 (95%-CI = [73, 142], Table 5) but this failed to reach statistical difference in severe exacerbations (RR = 0.17, 95%-CI = [0.02, 1.35], \( P = 0.093 \), \( I^2 = 0.0\% \)). Furthermore, the as-needed ICS/FABA regimen significantly reduced rescue medication required per day (SMD = −0.23, 95% CI = [−0.43, −0.02], \( P = 0.029 \), \( I^2 = 0.0\% \)) and improved FEV\(_1\)% predicted (SMD = 0.41, 95%-CI = [0.19, 0.62], \( P < 0.001 \), \( I^2 = 0.0\% \)) compared with the FABA regimen. In addition, we did not find any statistical difference in moderate to severe exacerbations (RR = 0.58, 95%-CI = [0.21, 1.57], \( P = 0.284 \)), severe exacerbations (RR = 0.12, 95%-CI = [0.01, 2.38], \( P = 0.166 \)), and other secondary outcomes (Table 5) between the ICS/FABA and regular ICS regimen.

In the children and adolescent subgroup, in comparison to the FABA regimen, the ICS/FABA regimen significantly reduced nocturnal awakenings times (SMD = −0.42, 95%-CI = [−0.75, −0.10], \( P = 0.010 \), Table 5) and improved FEV\(_1\)% predicted (SMD = 1.42, 95%-CI = [1.06, 1.79], \( P < 0.001 \)), but there was no statistical difference in moderate to severe exacerbations (RR = 0.63, 95%-CI = [0.32, 1.25], \( P = 0.170 \)), severe exacerbations (RR = 0.78, 95%-CI = [0.22, 2.81], \( P = 0.668 \)), and other secondary outcomes (Table 5) between the ICS/FABA and regular ICS regimen.
# Table 3: Subgroup analysis of exacerbations

| Comparisons                      | Exacerbations | Severe exacerbations |
|----------------------------------|---------------|----------------------|
|                                  | No. of Studies | ICS/FABA | FABA or ICS | RR (95% CI) | P value | Power | No. of Studies | ICS/FABA | FABA or ICS | RR (95% CI) | P value | Power |
| ICS/FABA vs. FABA regimen        |               |          |             |             |         |       |               |          |             |             |         |       |
| All                              | 4 [17, 27, 29, 30] | 42/348  | 68/295      | 0.56 (0.40, 0.78) | 0.001   | 1.00  | 3 [17, 27, 29] | 25/238  | 41/239      | 0.64 (0.44, 0.95) | 0.026   | 0.89  |
| Adult                            | 2 [17, 27]     | 6/167   | 26/165      | 0.24 (0.10, 0.54) | 0.001   | 0.98  | 2 [17, 27]     | 0/167   | 5/165       | 0.17 (0.02, 1.35) | 0.093   | 0.47  |
| Children and adolescent          | 2 [29, 30]     | 36/181  | 42/130      | 0.76 (0.53, 1.10) | 0.147   | 0.76  | 1 [29]         | 25/71   | 36/74       | 0.72 (0.49, 1.07) | 0.107   | 0.34  |
| ICS/FABA vs. ICS regimen         |               |          |             |             |         |       |               |          |             |             |         |       |
| All                              | 4 [17, 26, 29, 30] | 111/553 | 79/537      | 1.39 (1.08, 1.79) | 0.011   | 1.00  | 3 [17, 26, 29] | 94/443  | 70/427      | 1.34 (1.02,1.75) | 0.034   | 0.91  |
| Adult                            | 1 [17]         | 6/122   | 9/106       | 0.58 (0.21, 1.57) | 0.284   | 0.17  | 1 [17]         | 0/122   | 3/106       | 0.12 (0.01,2.38) | 0.166   | 0.22  |
| Children and adolescent          | 3 [26, 29, 30] | 105/481 | 70/431      | 1.50 (1.15, 1.96) | 0.003   | 1.00  | 2 [26, 29]     | 94/321  | 67/321      | 1.40 (1.07,1.84) | 0.014   | 0.81  |

*no. number, CI confidence interval, ICS inhaled corticosteroids, FABA fast-onset-acting \( \beta_2 \)-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting \( \beta_2 \)-agonist*
exacerbations (RR = 0.76, 95%-CI = [0.53, 1.10], P = 0.147, I² = 0.0%, Table 3) or severe exacerbations (RR = 0.72, 95%-CI = [0.49, 1.07], P = 0.107). When compared with the ICS regimen, the ICS/FABA regimen had higher exacerbations (RR = 1.50, 95%-CI = [1.15, 1.96], P < 0.001, I² = 18.4%) and severe exacerbations (RR = 1.40, 95%-CI = [1.07, 1.84], P = 0.014, I² = 0.0%), a significant reduction in the percentage of asthma symptom-free days (SMD = −0.27, 95%-CI = [−0.41, −0.14], P < 0.001, I² = 0.0%), more rescue medication required per day (SMD = 0.22, 95%-CI = [0.08, 0.35], P = 0.001, I² = 49.5%) and reduced FEV₁% predicted (SMD = −0.36, 95%-CI, [−0.69, −0.03], P = 0.033), but did not reach statistical significance on the nocturnal awakening times.

Safety

There were 9.4% (n = 58), 15.8% (n = 50) and 7.7% (n = 43) of participants who withdrew from the studies in the ICS/FABA regimen, the FABA regimen and the ICS regimen, respectively, which indicated more dropouts in the FABA regimen when compared to the ICS/FABA and the daily ICS regimens in the children and adolescent subgroup (Additional file 1: Table S3). It reported eight serious adverse events (such as bacterial pneumonia and hemoptysis) in all included studies (Additional file 1: Table S4), which had no difference between regimens. In terms of the linear growth. The study by Martinez et al [29] indicated that, compared with the FABA group, children with the daily use of ICS regimen grew 1.1 cm (SD = 0.3) less (P < 0.0001) during the 44-week treatment period, but no significant growth effect was found in children with the as-needed ICS/FABA regimen (0.3 cm, SD = 0.2, P = 0.26). During the 16-week treatment interval, Fitzpatrick et al [26] found that children with the as-needed use of ICS/FABA regimen grew 0.2011 cm (SE = 0.2097, P = 0.3381) higher than children with the daily use of ICS regimen.
Adherence of the daily use of ICS treatment

An additional meta-analysis was performed to pool the real-life adherence of the daily use of ICS treatment in patients with persistent asthma. The studies selection flow and characteristics of included studies were provided in the Methods and Results sections in the Additional file 1. The adherence of daily ICS regimen was calculated using the proportion of days covered (PDC) and defined as the total number of days with supply dispensed during the follow-up over the number of days of follow-up. Using a random-effects model, ICS adherence was 37.6% (95% CI = [33.1, 42.2], Additional file 1: Table S9).

Discussion

To our best knowledge, this is the first proof-of-concept systematic review and meta-analysis to systematically explore the efficacy and safety of the ICS/FABA regimen in single inhaler as reliever therapy in intermittent and mild asthma. Our study included the six trials with 1300 patients and suggests that the as-needed use of ICS/FABA regimen significantly reduces exacerbations, including severe exacerbations, nocturnal awakening, prolongs time to first exacerbation and improves FEV₁% predicted as compared to the as-needed FABA regimen, but it is inferior to the regular ICS regimen except for time to first exacerbation. The safety analysis indicated that the regular ICS regimen especially in a long-term treatment would lead to a small reduction in growth compared to either as-needed ICS/FABA or FABA regimens in the children and adolescent population. Our study shows that the ICS/FABA regimen in a single inhaler as a symptom-driven therapy would be a promising alternative regimen in management of intermittent or mild persistent asthma.

There are two important characteristics about the included RCTs for this meta-analysis. The first is the limited number of subjects involved in this meta-analysis, which resulted in under-powering with less than 0.80 to find statistical difference in some outcomes, especially in the sub-group meta-analysis, although most of the included studies calculated adequate power for their specific primary outcomes rather than ours in this...
Table 4 The quality of evidence assessment for as-needed use of ICS/FABA in intermittent and mild asthma by GRADE approach

| Outcome No. of participants (studies) | Relative effect (95% CI) | Anticipated absolute effects (95% CI) | Certainty | What happens |
|---------------------------------------|--------------------------|---------------------------------------|-----------|--------------|
|                                       |                          | Comparison group | Intervention group | Difference |             |
| ICS/FABA compared to FABA for intermittent or mild persistent asthma |                          |                          |             |              |
| Exacerbations follow up: range 12 weeks to 44 weeks | RR 0.56 (0.40 to 0.78) | 23.1% | 12.9% (92 to 18.0) | 10.1% fewer (13.8 fewer to 5.1 fewer) | MODERATEa | Compared with the as-needed FABA regimen, the as-needed use of ICS/FABA as monotherapy probably reduces moderate to severe exacerbations |
| Severe exacerbations follow up: range 24 weeks to 44 weeks | RR 0.64 (0.44 to 0.95) | 17.2% | 11.0% (7.5 to 16.3) | 6.2% fewer (9.6 fewer to 09 fewer) | MODERATEa | Compared with the as-needed FABA regimen, the as-needed use of ICS/FABA as monotherapy probably reduces severe exacerbations |
| Time to first exacerbation follow up: range 12 weeks to 44 weeks | HR 0.520 (0.345 to 0.783) | 27.0% | 15.1% (10.3 to 21.9) | 11.9% fewer (16.7 fewer to 5.1 fewer) | MODERATEa | Compared with FABA regimen, ICS/FABA regimen probably reduces the HR for the time to first exacerbation |
| ICS/FABA compared to ICS for intermittent or mid persistent asthma |                          |                          |             |              |
| Exacerbations follow up: range 12 weeks to 44 weeks | RR 1.39 (1.08 to 1.79) | 14.7% | 204% (159 to 26.3) | 5.7% more (12 more to 11.6 more) | MODERATEa | Compared with regular ICS regimen, the as needed ICS/FABA regimen probably has slightly higher risk of moderate to severe exacerbations |
| Severe exacerbations follow up: range 16 weeks to 44 weeks | RR 1.34 (1.02 to 1.75) | 16.4% | 220% (167 to 28.7) | 5.6% more (03 more to 12.3 more) | MODERATEb | Compared with regular ICS regimen, the as needed ICS/FABA regimen probably has slightly higher risk of severe exacerbations |
| Time to first exacerbation | HR 1.295 (0.805 to 2.083) | 11.1% | 14.1% (90 to 21.8) | MODERATEa |              |
Table 4: The quality of evidence assessment for as-needed use of ICS/FABA in intermittent and mild asthma by GRADE approach (Continued)

| Outcome | No. of participants (studies) | Relative effect (95% CI) | Anticipated absolute effects (95% CI) | Certainty | What happens |
|---------|------------------------------|--------------------------|--------------------------------------|-----------|--------------|
|         |                              |                          | Comparison group | Intervention group | Difference |               |
| Follow up: range 12 weeks to 44 weeks | No. of participants: 591 (3 RCTs) [17, 29, 30] | 3.0% more (2.1 fewer to 10.6 more) | 3.0% more (2.1 fewer to 10.6 more) | MODERATE | Compared with regular ICS regimen, the as needed ICS/FABA regimen probably increases the HR for the time to first exacerbation |
| ICS compared to FABA for intermittent or mild persistent asthma Patient or population: intermittent or mild persistent asthma Setting: inpatients and outpatient Intervention: ICS Comparison: FABA Time to first exacerbation follow up: range 12 weeks to 44 weeks | No. of participants: 536 (3 RCTs) [17, 29, 30] | HR 0.420 (0.274 to 0.644) 27.0% 12.4% (8.3 to 18.4) 14.6% fewer (18.7 fewer to 8.7 fewer) | 14.6% fewer (18.7 fewer to 8.7 fewer) | MODERATE | Compared with FABA regimen, regular ICS regimen probably reduces the HR for the time to first exacerbation |

The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

GRADE Working Group grades of evidence:
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of the effect.

No. number, CI confidence interval, RR risk ratio, HR hazard ratio

*aThe results obtained for different diagnostic criteria of asthma and beclomethasone equivalent consumption
bThe results obtained for different beclomethasone equivalent consumption
### Table 5 Summary of findings for secondary outcomes

| Comparisons | Nocturnal awakenings (no.) | Symptom-free days (%) |
|-------------|---------------------------|-----------------------|
|             | No. of Studies | SMD  | 95% CI       | p value | %2-squared (%) | Power | No. of Studies | SMD  | 95% CI       | p value | %2-squared (%) | Power |
| ICS/FABA regimen vs. FABA regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 2 [17, 30]     | −0.290 | [−0.490, −0.000] | 0.004 | 8.7 | 0.06 | 4 [17, 27, 29, 30] | 0.083 | [−0.074, 0.240] | 0.303 | 22.9 | 0.94 |
| Adult       | 1 [17]         | −0.207 | [−0.461, 0.047] | 0.110 | − | 0.48 | 2 [17, 27] | 0.068 | [−0.147, 0.284] | 0.534 | 0.0 | 0.16 |
| Children and adolescent | 1 [30] | −0.0427 | [−0.752, −0.102] | 0.010 | − | 0.82 | 2 [29, 30] | 0.099 | [−0.131, 0.329] | 0.398 | 71.0 | 0.94 |
| ICS/FABA regimen vs. ICS regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 2 [17, 30]     | −0.098 | [−0.284, 0.087] | 0.299 | 0.0 | 0.57 | 4 [17, 26, 29, 30] | −0.253 | [−0.373, −0.132] | <0.001 | 0.0 | 0.81 |
| Adult       | 1 [17]         | −0.026 | [−0.286, 0.234] | 0.845 | 0.0 | 0.07 | 1 [17] | −0.160 | [−0.421, 0.100] | 0.228 | − | 0.32 |
| Children and adolescent | 1 [30] | −0.173 | [−0.438, 0.091] | 0.200 | − | 0.36 | 3 [26, 29, 30] | −0.278 | [−0.414, −0.142] | <0.001 | 0.0 | 0.66 |
| ICS regimen vs. FABA regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 2 [17, 30]     | −0.138 | [−0.290, 0.014] | 0.012 | 0.0 | 0.06 | 3 [17, 29, 30] | 0.275 | [0.102, 0.448] | 0.002 | 0.0 | 1.00 |
| Adult       | 1 [17]         | −0.212 | [−0.475, 0.051] | 0.115 | − | 0.07 | 1 [17] | 0.249 | [−0.015, 0.512] | 0.064 | − | 0.56 |
| Children and adolescent | 1 [30] | −0.0335 | [−0.658, −0.011] | 0.043 | − | 0.64 | 2 [29, 30] | 0.295 | [0.065, 0.525] | 0.012 | 408 | 0.99 |
| Comparisons | Rescue medication required per day | FEV1% of predicted value |
|             | No. of Studies | SMD  | 95% CI       | p value | %2-squared (%) | Power | No. of Studies | SMD  | 95% CI       | p value | %2-squared (%) | Power |
| ICS/FABA regimen vs. FABA regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 5 [17, 27–30]  | −0.138 | [−0.290, 0.014] | 0.076 | 18.0 | 0.98 | 3 [17, 27, 29] | 0.773 | [0.105, 1.441] | 0.023 | 91.3 | 1.00 |
| Adult       | 3 [17, 27, 28] | −0.226 | [−0.429, −0.023] | 0.029 | 0.0 | 0.52 | 2 [17, 27] | 0.405 | [0.188, 0.623] | <0.001 | 0.0 | 0.94 |
| Children and adolescent | 2 [29, 30] | −0.025 | [−0.254, 0.205] | 0.834 | 46.0 | 0.34 | 1 [29] | 1.429 | [1.064, 1.794] | <0.001 | − | 1.00 |
| ICS/FABA regimen vs. ICS regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 5 [17, 26, 28–30] | 0.192 | [0.075, 0.309] | 0.001 | 16.2 | 1.00 | 2 [17, 29] | −0.061 | [−0.629, 0.506] | 0.832 | 863 | 0.96 |
| Adult       | 2 [17, 28]     | 0.097 | [−0.141, 0.335] | 0.424 | 0.0 | 0.20 | 1 [17] | 0.219 | [−0.042, 0.480] | 0.100 | − | 0.50 |
| Children and adolescent | 3 [26, 29, 30] | 0.222 | [0.088, 0.356] | 0.001 | 49.5 | 0.91 | 1 [29] | −0.360 | [−0.691, −0.030] | 0.033 | − | 0.68 |
| ICS regimen vs. FABA regimen |              |      |              |         |               |       |              |      |              |         |               |       |
| All         | 4 [17, 28–30]  | −0.152 | [−0.318, 0.004] | 0.073 | 0.0 | 0.87 | 2 [17, 29] | 0.415 | [−0.102, 0.933] | 0.001 | 832 | 1.00 |
| Adult       | 2 [17, 28]     | −0.227 | [−0.468, 0.061] | 0.065 | 0.0 | 0.56 | 1 [17] | 0.161 | [−0.101, 0.424] | 0.229 | − | 0.33 |
| Children and adolescent | 2 [29, 30] | −0.0084 | [−0.313, 0.004] | 0.471 | 55.1 | 0.53 | 1 [29] | 0.690 | [0.356, 1.024] | <0.001 | − | 0.99 |

*no.* number, SMD standardized mean difference, CI confidence interval, ICS inhaled corticosteroids, FABA fast-onset-acting β2-agonist, ICS/FABA inhaled corticosteroids/fast-onset-acting β2-agonist
study. The second is all included studies were completed in an ideal setting but not in real-world conditions [33], because all included subjects were requested to have an adherence of more than 75% before recruitment. In the real-world setting, the adherence of daily ICS was only 37.6% (95% CI = [33.1, 42.2]) in our additional meta-analysis. Therefore, the regular ICS regimen would not be more effective than the as-needed ICS/FABA strategy as poor adherence to ICS is correlated with asthma-related outcomes [34].

Despite effective pharmacological options for treating asthma, most patients fail to achieve good control in the real world. Non-adherence is common, with over-reliance on SABA and under-use of ICS frequently being observed. Therefore, there is a real need to consider new approaches to improve outcomes. One regimen that has attracted attention and controversy is single inhaler for maintenance and relief therapy (SMART). The SMART or single inhaler therapy (SiT) means that a single inhaler contains two drugs. One of these drugs acts quickly and termed the ‘reliever’, and the other one works much more slowly and is called the ‘preventer’. Patients on SMART have one inhaler for use every day to control their underlying inflammation and also for symptom relief. The timely ICS use at the time of increased symptoms can improve asthma outcomes by reducing exacerbation risk [35]. In recent decades, evidence has demonstrated that using combined ICS and FABA as reliever medication can reduce the exacerbation rate [36–38] and have a lower total ICS exposure, without compromising outcomes against current best practice strategies using a fixed-dose ICS/LABA combination inhaler. But most of this evidence comes from moderate to severe asthma patients, who have a greater risk of exacerbations. Thus, GINA [1] recommended ICS/formoterol, a ICS/FABA inhaler, as reliever medication for moderate to severe asthma patients except for patients with intermittent and mild asthma. In our study, we extended this efficacy to the population with intermittent and mild asthma in significant improvements of nocturnal awakening times, FEV\(_1\)% predicted, exacerbations and the time to first exacerbation compared the as-needed use of ICS/FABA regimen with the as-needed FABA regimen.

A possible concern with as-needed ICS/FABA is that inadequate anti-inflammatory treatment may be given to some patients, who would be at higher risk of exacerbations. Treatment with daily ICS at low doses decreases the risk of severe exacerbations and improves asthma control in patients with mild persistent asthma [39, 40]. Good adherence is needed for the efficiency of daily ICS therapy, but patients trend to use ICS intermittently and occasionally [15, 16]. Previous research has shown that nonadherence of ICS results in poor clinical control and increases school and work absenteeism, unscheduled healthcare utilization, morbidity, and mortality [34, 41, 42]. We performed an additional meta-analysis in the adherence of the daily ICS therapy in a real-world setting in this study, and found the real-life adherence of daily use of ICS was 37.6% (95% CI = [33.1, 42.2]) with obvious heterogeneity between real-world RCTs and observational studies (Additional file 1: Table S9), while, it was more than 75% in our included studies significantly related to the reduced asthma exacerbations [43]. With regard to potential corticosteroid side effects, treatment with the as-needed ICS/FABA regimen was characterized by a lower average ICS dose and in children or adolescent population, by a higher linear growth than treatment with regular daily ICS regimen.

Based on the results of our study, the current recommendation from guidelines that regular ICS should be initiated only when patients use their SABA more than twice per week needs to be revisited, because the evidence that this approach works in real-life clinical practice is limited. The potential benefits of this approach were compromised by both low rates of ICS prescription in patients, even in the setting of poor control, and poor adherence by patients who were prescribed ICS regimen. Accordingly, the as-needed ICS/FABA regimen would be a promising alternative therapy, which might represent an effective, safe, and novel therapy for the treatment of intermittent and mild asthma. It may be particularly useful for selected patients who adhere poorly to their regular daily ICS regimen.

From a clinical point of view, the as-needed use of ICS/FABA regimen is a promising choice for the long-term management of intermittent and mild asthma. Exacerbations are major determinants of the direct cost of asthma, and preventing exacerbations is one of the key goals in asthma management [44]. In our study, compared with the as-needed use of FABA regimen, the as-needed use of ICS/FABA as monotherapy statistically reduced moderate to severe exacerbations and severe exacerbations. In addition, the number of patients that need to be treated for one of them to benefit from decreased moderate to severe exacerbations compared with the as-needed use of FABA regimen was 10 (the number of moderate to severe exacerbations that to be decreased from treating 1000 patients compared with the as-needed use of FABA regimen was 101 (95%-CI = [51, 138])) and the number of patients that need to be treated for one of them to benefit from decreased severe exacerbations compared with the as-needed use of FABA regimen was 16 (the number of severe exacerbations that to be decreased from treating 1000 patients compared with the as-needed use of FABA regimen was 62 (95%-CI = [9, 96])). On the other hand, as
we had mentioned above, good adherence is needed for the efficiency of daily ICS therapy, and there are some interventions to improve adherence to ICS may take many forms, including audiovisual reminders [45, 46], electronic monitoring [46], interactive voice response system via mobile phone [47], text message reminders [48] and parent education [49]. However, the magnitude of the improvements in adherence was generally not large (range from 4% to 20%) [50]. This improvement does not ensure the good adherence of ICS regimen (75%). Besides, the successful interventions to promote adherence were complex and multi-faceted and included combinations of counseling, education, more convenient care, self-monitoring, reinforcement, reminders, and other forms of additional attention or supervision [51, 52].

There are several limitations to this study that needs to be addressed. First, this study aimed to demonstrate the proof-of-concept whether the ICS/FABA in a single inhaler as reliever therapy in intermittent and mild persistent asthma was feasible in clinical practice, therefore two of included studies [29, 30] involved the use of the ICS and the FABA in separate inhalers but not in a single inhaler. Second, we included the limited number of studies that had inadequate power to find some difference in the subgroup analysis. Third, we used GetData Graph Digitizer to mine data and the Cochrane handbook recommended principals to deal with missing data, which would result in some potential impact on outcomes. Fourth, there was obvious heterogeneity in some outcomes such as the moderate to severe exacerbations, but it could be partly explained by different age groups. Fifth, all included RCTs were completed in an ideal condition with more than 75% of adherence rather than a real-world setting. To provide additional information in real-life adherence of regular ICS regimen, we pooled the rates of adherence across real-world RCTs and observational studies.

Conclusions
In conclusion, our study suggests that the as-needed use of ICS/FABA regimen significantly reduces exacerbations, nocturnal awakening times, extend time to first exacerbation and improves FEV₁% predicted compared to the as-needed FABA regimen, but it is inferior to the regular ICS regimen except for time to first exacerbation. With regard to potential corticosteroid side effects, it indicated that the regular ICS regimen especially in a long-term treatment would lead to grow less than either the as-needed ICS/FABA or FABA regimens in the children and adolescent population. This study displays that the ICS/FABA regimen in a single inhaler as a symptom-driven therapy would be a promising alternative regimen particularly for the very patients with intermittent or mild asthma who adhere poorly to their regular ICS regimen. However, further real-world RCTs are needed to confirm these findings.

Additional files

**Additional file 1**: The online material of corticosteroid plus β₂-agonist in a single inhaler as reliever therapy in intermittent and mild asthma: A proof-of-concept systematic review and meta-analysis. (DOCX 80 kb)

**Abbreviations**
BDP: Beclomethasone dipropionate; CI: Confidence interval; FEV₁: Forced expiratory volume in one second; HR: Hazard ratio; ICS: Inhaled corticosteroids; ICS/FABA: The combination corticosteroid/fast-onset-acting β₂-agonist; LABA: Long-acting β₂-agonists; NNT: The number needed to treat; NNTB: The number needed to treat for an additional beneficial outcome; PDC: The proportion of days covered; RR: Risk ratio; SABA: Short-acting β₂-agonist; SMD: The standardized mean difference

**Acknowledgements**
All authors thank Prof. Eric D. Bateman, Division of Pulmology, Department of Medicine, University of Cape Town, South Africa, for providing important intellectual comments to this manuscript.

**Funding**
This study was supported by the National Natural Science Foundation of China (no. 81370122, 81570023 and 81670023), Science and Technology Foundation of Sichuan Province (2015ZZ0021), Science and Technology Foundation of Chengdu (2014-HW01-00204-SP), the Youth Science Funding of Sichuan University (no. 2011SCU04817), and the Program for New Century Excellent Talents in University (no. NCET-12-0380).

**Availability of data and materials**
The authors declare that all data supporting the findings of this study are available within the following articles and its supplementary information files.
1. Fitzpatrick AM, Jackson DJ, Mauger DT, Boehler SJ, Phipatanakul W, Sheehan WJ, et al. Individualized Therapy for Persistent Asthma in Young Children. J Allergy Clin Immunol. 2016;138(6):1608-1618. http://www.sciencedirect.com/science/article/pii/S0091674916312179
2. Haahntela T, Tamminen K, Malmberg LP, Zetterstrom O, Karjalainen J, Yla-Outinen H, et al. Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study. The European respiratory journal. 2006;28(4):748–55. http://erej.ersjournals.com/content/erj/28/4/748.full.pdf
3. Lazarinis N, Jorgensen L, Ekstrom T, Bjørner L, Dahlen B, Pullerits T, et al. Combination of budesonide/formoterol in demand improves asthma control by reducing exercise-induced bronchoconstriction. Thorax. 2014;69(2):130–6. http://thorax.bmj.com/content/thoraxjnl/69/2/130.full.pdf
4. Martinez MD, Chinchilli VM, Morgan WJ, Boehler SJ, Lemanske RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet (London, England). 2011;377(9765):650–7. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852146/
5. Papa A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. The New England journal of medicine. 2007;356(20):2040–52. http://www.nejm.org doi:10.1056/nejmoa063861
6. Papa A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, et al. Regular vs pr nebulized treatment in wheeze preschool children. Allergy. 2009;64(10):1463–71. http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2009.02134.x/epdf

**Authors’ contributions**
GW made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data and drafting the manuscript. XZ made substantial contributions to conception and design, acquisition of data, and analysis and interpretation of data. HPZ made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data and drafting the manuscript. LW made substantial contributions to conception and design, acquisition of data, analysis and interpretation of data and drafting the manuscript. Excellent Talents in University (no. NCET-12-0380).
conception and design, acquisition of data, analysis and interpretation of data, and drafting the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
PJ. Barnes has served on Scientific Advisory Boards of AstraZeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Johnson & Johnson, Napp, Novartis, Takeda, Pfizer, Prosonic, RespVient, Teva and Zambon and has received research funding from AstraZeneca, Boehringer-Ingelheim, Chiesi, Novartis and Takeda. GW, XZ, HPF, LW, DYY and GW declare that there are no competing interests associated with the study.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China. 2Pneumology Group, Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu 610041, People’s Republic of China. 3West China School of Medicine, Sichuan University, Chengdu 610041, People’s Republic of China. 4Department of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, China. 5National Heart & Lung Institute, Imperial College, London, UK.

Received: 10 September 2017 Accepted: 5 November 2017
Published online: 06 December 2017

References
1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2016. Available from: www.ginasthma.org.
2. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy. 2004;59(Suppl 5):469–78.
3. The Global Asthma Report. Auckland, New Zealand: Global Asthma Network, 2014. Available from: http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2014.pdf.
4. Chung KF, Wenzel SE, Brozek JI, Bush A, Castro M, Sorkin JR, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73.
5. Jarjour NN, Erzurum SC, Bleecker ER, Calhoun WJ, Castro M, Comhair SA, et al. Severe and fatal asthma in the severe asthma network. J Thorac Dis. 2017;9(5):1333–44.
6. Kong KT, O’Callaghan CA, O’Byrne PM, Taylor CR, Wenzel S, et al. Longitudinal analysis of beclomethasone dipropionate for the control of asthma in Australian children aged 4–18 years. Thorax. 2016;71(5):451–8.
7. Kwok MY, Walsh-Kelly CM, Gorelick MH, Grubowski L, Kelly KJ. National Asthma Education and Prevention program severity classification as a measure of disease burden in children with acute asthma. Pediatrics. 2006;117(4 Pt 2):S71–7.
8. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):1–7.
9. Wang L, Liang R, Zhou T, Zheng J, Liang BM, Zhang HP, et al. Identification and validation of asthma phenotypes in Chinese population using cluster analysis. Ann Allergy Asthma Immunol. 2017;119(4):32–42.
10. Ding B, Ma W, Wang Y. Analysis of true asthma prevalence. Chin Med J (Engl). 2008;121(2):149–52.
11. Using beta 2-stimulants in asthma. Drug Ther Bull. 1997;35(1):1–4. http://dtb.bmj.com/content/35/1/1.long.
36. Scicchitano R, Albers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20(9):1403–18.
37. O’Byrne PM, Bisgaard H, Godard PP, Proteles M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005;172(2):129–36.
38. Cates C, Kamer C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;4:CD007313.
39. Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet. 2003;361(9363):1071–6.
40. O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1392–7.
41. Birkhead G, Attaway NJ, Strunk RC, Townsend MC, Teutsch S. Investigation of a cluster of deaths of adolescents from asthma: evidence implicating inadequate treatment and poor patient adherence with medications. J Allergy Clin Immunol. 1989;84(4 Pt 1):484–91.
42. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98(6 Pt 1):1051–7.
43. Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–91.e2.
44. Fitzgerald JM, Bateman E, Hurd S, Boulet LP, Haashtela T, Cruz AA, et al. The GINA asthma challenge: reducing asthma hospitalisations. Eur Respir J. 2011;38(5):997–8.
45. Charles T, Quinn D, Weatherall M, Aldington S, Beasley R, Holt S. An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. J Allergy Clin Immunol. 2007;119(4):811–6.
46. Onyirimba F, Apter A, Resine S, Litt M, McCusker C, Connors M, et al. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. Ann Allergy Asthma Immunol. 2003;90(4):411–5.
47. Mulvany Æ, Ho YK, Cala CM, Chen Q, Nian H, Patterson BL, et al. Assessing adolescent asthma symptoms and adherence using mobile phones. J Med Internet Res. 2013;15(7):e141.
48. Johnson KB, Patterson BL, Ho YK, Chen Q, Nian H, Davison CL, et al. The feasibility of text reminders to improve medication adherence in adolescents with asthma. JAMA. 2016;323(3):449–55.
49. Bender BG. Overcoming barriers to nonadherence in asthma treatment. J Allergy Clin Immunol. 2002;109(6 Suppl):S554–9.
50. Normansell R, Kew KM, Stovold E. Interventions to improve adherence to inhaled steroids for asthma. Cochrane Database Syst Rev. 2017;4:CD012226.
51. Haynes RB, McDonald H, Garg AX, Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2002;2:CD000011.
52. Clarenbach CF, Nicod LP, Kohler M. Real-world asthma management with inhaler devices in Switzerland-results of the asthma survey. J Thorac Dis. 2016;8(11):3096–104.
53. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2014;69(Suppl 1):1–192.
54. Chinese Medical Association of respiratory disease branch. Asthma Study Group. [The Chinese guideline for asthma management and prevention]. Zhonghua Jie He He Hu Xi Za Zhi 2016;39(9):675–697. doi:https://doi.org/10.3760/cma.j.issn.1001-0939.2016.09.007. Chinese.
55. GEMA. 2009 (Spanish guideline on the management of asthma). J Investig Allergol Clin Immunol. 2010;20(Suppl 1):1–59.
56. Ichinose M, Sugiura H, Nagase H, Yamaguchi M, Inoue H, Sagara H, et al. Japanese guidelines for adult asthma 2017. Allergol Int. 2017;66(2):163–89.
57. Al-Moamary MS, Alhaider SA, Idriss MM, Al Gohbain MO, Zeitouni MO, Al-Harbi AS, et al. The Saudi initiative for asthma - 2016 update: guidelines for the diagnosis and management of asthma in adults and children. Ann Thorac Med. 2016;11(1):3–42.